Luoyi

Luoyi Biological Technology is a Shanghai-based biotechnology company specializing in the development of next-generation RNA therapeutics, with a primary focus on circular RNA (circRNA) and gene editing technologies. Founded by experts in RNA biology, the company aims to overcome the limitations of traditional linear mRNA, such as short half-life and transient expression, by utilizing the inherent stability of circularized RNA structures. Luoyi has established a proprietary platform for circRNA design, high-efficiency synthesis, and delivery via advanced lipid nanoparticles (LNPs). The company's pipeline targets a broad range of medical needs, including prophylactic vaccines for infectious diseases and therapeutic applications in oncology and protein replacement. Luoyi has secured significant venture capital backing to advance its preclinical programs toward clinical validation.